Epilepsy and Other Seizure Disorders

Stroke and Transient Ischemic Attack

We *SEE* You! Nominations Open For EBCI’s 2020 National “HOPE AWARD”…

Hi guys!  One of my most favorite things to do under my leadership of the EndBrainCancer Initiative is to talk directly to patients with...

Today Would Have Been our 2020 Bellingham Brain Cancer Walk….

Today, May 31, 2020, the very last day of #BBCA month, I find myself reflecting on many things and just looked through the photos...

NCI-CONNECT and BTTC 2019 Meetings Summary

June 3, 2019, by NCI-CONNECT Staff 2019 Meeting Attendees Credit: NCI-CONNECT Staff The 2019 NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) and Brain Tumor Trials Collaborative (BTTC) Annual Meetings were...

Let’s Write a Book Together to Help Others!

Thank you so much for your interest in submitting your story for my collaborative book.  First, let me tell you more about myself and...

Parkinson’s and Movement Disorders

Stay Connected

16,985FansLike
2,458FollowersFollow
61,453SubscribersSubscribe

Stroke

Parkinson’s and Movement Disorders

A Phase I Study of PLX8394 Plus Ritonavir in Children with Recurrent or Progressive BRAF Activated Gliomas – A Kids’ Brain Tumor Cure Foundation

A Phase I Study of PLX8394 Plus Ritonavir in Children with Recurrent or Progressive BRAF Activated Gliomas Principal Institutions: Children’s Hospital of Los Angeles in...

Clinical Trials and Expanded Access to Experimental Drugs/Devices Get a Boost from Recent Legislation – A Kids’ Brain Tumor Cure Foundation

When you or a family member is diagnosed with a serious or life-threatening disease, you have choices to make about your treatment once standard...

Dementias

ITS NOT A TUMOR

submitted by /u/WeirdlyTechnical Continue Reading to the Source

Living Through Covid-19 as a Cancer Patient or Survivor

https://www.cancertalkfoundation.org/post/living-through-covid-19-as-a-cancer-patient-or-survivor submitted by /u/CancerTalkFoundation Continue Reading to the Source

Is this residual tumour vs. ???

submitted by /u/bingbongbello Continue Reading to the Source

Brain Tumor

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalitions Network...

Impact on Cancer Patient Organisations Worldwide in 2020 – IBTA

First Coalition Connection event sees publication of report showing devastating impact of COVID-19 on cancer organisations  On 4th February 2021, the Global Cancer Coalitions Network...

How has COVID-19 affected the global cancer community? – IBTA

Save the date: Coalition Connection: COVID-19 on 4 February 06:30am PST/ 09:30am EST/ 02:30pm GMT/ 03:30pm CET On 4th February 2021, the Global Cancer Coalition Network...
Advertisment

LATEST ARTICLES

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Salma Jabbour, MD, on Next Steps for the KEYNOTE-799 Study

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study...

Most Popular

Lower-Dose Hypofractionated Radiotherapy Schedule Proves Effective for Patients With Locally Advanced Bladder Cancer

Using a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks to treat patients with locally advanced bladder cancer was noninferior to...

Study Identifies New Biomarker Which Could Predict Response to CD40 Immunotherapy in Pancreatic Cancer

Research published in JCI Insight identified systemic inflammation as a possible resistance mechanism to a CD40–based chemoimmunotherapy in patients with advanced pancreatic cancer.1According to...

Significant Interfacility Variation Found in Implementation of Low-Value Breast Cancer Procedures

A number of facility-level characteristics were associated with the use of low-value breast cancer procedures, and interfacility variation presented an opportunity for formal de-implementation...

KarMMa Trial Results for Ide-Cel in Refractory Myeloma Show Favorable Efficacy

Chimeric antigen receptor (CAR) T-cell therapy with idecabtagene vicleucel (ide-cel) induced responses in almost 75% of patients with multiple myeloma following relpase on multiple...